On May 29, 2019 OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of cancer, reported that Chief Executive Officer William Annett will present a company overview at the 2019 BIO International Convention, which is being held June 3 – 6, 2019 at the Pennsylvania Convention Center in Philadelphia (Press release, BioTime, MAY 29, 2019, View Source;p=RssLanding&cat=news&id=2400014 [SID1234536676]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation details:
Date: Wednesday, June 5
Time: 10:45am EDT
Location: Theatre 2
A live webcast of the presentation can be access using the following link: http://www.veracast.com/webcasts/bio/internationalconvention2019/81201224287.cfm

A replay of the webcast will be available through September 3, 2019.

About the BIO International Convention

The BIO International Convention is hosted by the Biotechnology Innovation Organization (BIO), which represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations.

The Convention allows for public and private companies to provide company presentations, request meetings with biotech investors and executives, attend educational sessions and engage in networking opportunities.

For more information, please visit: View Source

About DetermaVu

DetermaVu is being developed as an intermediate step to confirm the absence of cancer between imaging modalities (LDCTs) detecting suspicious lung nodules and downstream invasive procedures that determine if the nodules are malignant. OncoCyte estimates that a $2 billion to $4.7 billion annual market could develop in the U.S. for its confirmatory lung cancer liquid biopsy test, depending on the scope of physician utilization, market penetration and reimbursable pricing.

DetermaVu has the potential to dramatically reduce U.S. healthcare costs by billions of dollars each year by eliminating unnecessary biopsies, which, according to a study of Medicare data by an independent health economics firm, cost on average $14,634 each. In addition, DetermaVu can provide great benefit to patients by avoiding invasive biopsies and the complications that arise in up to 24% of those procedures, and deaths that occur in up to 1% of cases.

DetermaVu is a trademark of OncoCyte Corporation

On May 29, 2019 Spectrum Pharmaceuticals (NasdaqGS: SPPI) reported that an overview of the company’s business strategy and development-stage programs will be given at the Jefferies 2019 Global Healthcare Conference being held in New York (Press release, Spectrum Pharmaceuticals, MAY 29, 2019, http://investor.sppirx.com/news-releases/news-release-details/spectrum-pharmaceuticals-present-corporate-update-jefferies-2019 [SID1234536645]). The company presentation is on Wednesday, June 5, 2019, at 3:30 PM EDT.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of Spectrum’s presentation will be available at View Source

On May 29, 2019 AgilVax, Inc., a biotechnology company developing targeted antibody-based therapies for the treatment of various cancers, including metastatic breast cancer (MBC), reported that the company has triggered Phase II funding of $2 million from its Fast Track Small Business Innovation Research (SBIR) grant awarded by the National Cancer Institute (NCI) (Press release, Agilvax, MAY 29, 2019, View Source [SID1234536661]). AgilVax accomplished its Phase I goals ahead of schedule, which enabled the early initiation of the Phase II portion of the grant. Phase II is focused on studies that support an Investigational New Drug (IND) application for AgilVax’s lead product, AX09. As a result of the grant award, AgilVax selected a prominent Contract Manufacturing Organization (CMO) and initiated cGMP manufacturing of AX09.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

AX09 is being developed as an antibody-based therapy for the treatment of MBC by inhibiting the function of xCT, which is associated with tumor growth and metastatic progression. xCT overexpression occurs in several cancers leading to overarching metabolic changes that reprogram cells for tumor growth and survival. AgilVax’s AX09 shows significant anti-xCT immune response in preclinical breast cancer models, where tumor impairment and reduced metastatic progression have been demonstrated. Several peer reviewed publications elucidate the preclinical evidence of AX09 and the importance of xCT in cancer metastasis.

Dr. Federica Pericle, President and CEO of AgilVax and Principal Investigator, stated, "Initiating the GMP manufacturing program for AX09 is an important milestone for the company. We are now one-step closer to the clinic, where we can provide patients suffering from metastatic breast cancer and other cancers a novel therapeutic option. We are also grateful to NCI for the continued support, which is instrumental in supporting the development of AX09."

On May 29, 2019 MaxCyte reported that Doug Doerfler, Chief Executive Officer, will provide a company overview at the 2019 BIO International Convention on Wednesday, June 5, at 1:15 p.m. ET at the Pennsylvania Convention Center in Philadelphia (Press release, MaxCyte, MAY 29, 2019, View Source [SID1234537619]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In his presentation, Mr. Doerfler will discuss:

The status of MaxCyte’s Phase I dose-escalation clinical trial with MCY-M11, a wholly-owned non-viral mRNA-based therapeutic candidate from MaxCyte’s CARMA platform. Investigators recently began dosing in the trial’s second cohort of individuals with relapsed/refractory ovarian cancer and peritoneal mesothelioma. MaxCyte is one of a small number of companies with a cell therapy for solid tumours in the clinic, and successful dosing represents MaxCyte’s unique approach to chimeric antigen receptor ("CAR") therapy, including its rapid manufacturing process.
MaxCyte’s commercial momentum including new multi-drug commercial agreements signed with CRISPR Therapeutics, Precision BioSciences and with Kite, a Gilead Company. All programs enable non-viral cell engineering for development of multiple CAR-T drug candidates. MaxCyte’s total number of cell therapy partnered program licenses total more than 70 including more than 35 partnered program licensed for clinical development.
MaxCyte’s newly launched next generation of commercially-oriented instruments and consumables, under the ExPERT brand. This includes three instrument formats with enhanced design and functionality, coupled with a wider range of consumables that offer expanded utility from early research to clinical and commercial use.

For more information about the conference, please visit: //convention.bio.org/

On May 29, 2019 Bausch Health Companies Inc. (NYSE/TSX: BHC) reported that the Company will participate in two investor conferences in June (Press release, Valeant, MAY 29, 2019, View Source [SID1234536630]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Paul S. Herendeen, executive vice president and chief financial officer, Arthur J. Shannon, senior vice president and head of Investor Relations and Communications, and William Woodfield, vice president and treasurer, are scheduled to participate at the Barclays High Yield Bond & Syndicated Loan Conference in Colorado Springs, Colo., on June 6, 2019 at 10:50 a.m. MDT (12:50 p.m. EDT).

Joseph C. Papa, chairman and chief executive officer, Sam Eldessouky, senior vice president and corporate controller, and Arthur J. Shannon, senior vice president and head of Investor Relations and Communications, are scheduled to participate at the BMO Prescription for Success Healthcare Conference in New York on June 25, 2019 at 10:00 a.m. EDT.

Live webcasts and audio archives of the presentations will be available on the Investor Relations page of the Bausch Health Companies Inc. web site at: View Source